PUBLISHER: The Business Research Company | PRODUCT CODE: 1939228
PUBLISHER: The Business Research Company | PRODUCT CODE: 1939228
Angioplasty balloons are medical tools utilized to alleviate narrowed or obstructed blood vessels within the body. Commonly employed in addressing conditions such as coronary artery disease and peripheral artery disease, these balloons function by expanding within the artery, exerting pressure on plaque deposits to restore blood flow.
Angioplasty balloons come in several types, including normal balloons, scoring balloons, drug-eluting balloons, and cutting balloons. Normal balloons represent the fundamental angioplasty devices lacking specialized features, intended for the dilation of narrowed or blocked blood vessels through inflation. These balloons are fabricated from various materials such as non-compliant and semi-compliant substances. They find application across a spectrum of procedures, including coronary and peripheral angioplasty, and are utilized by diverse end-users including hospitals, specialty clinics, catheterization laboratories, ambulatory surgical centers, among others.
Tariffs are influencing the angioplasty balloons market by increasing import costs for balloon catheters, polymer materials, inflation systems, and precision manufacturing components sourced through global supply chains, thereby raising procurement and procedure costs for hospitals, specialty clinics, and catheterization laboratories. The impact is more pronounced in Asia-Pacific, Latin America, and Middle Eastern markets that rely heavily on imported non-compliant, drug-eluting, and scoring balloon products. However, tariffs are also encouraging regional manufacturing, localized assembly, and supplier diversification, which can strengthen domestic production capabilities and improve long-term supply resilience across key product segments.
The angioplasty balloons market research report is one of a series of new reports from The Business Research Company that provides angioplasty balloons market statistics, including angioplasty balloons industry global market size, regional shares, competitors with a angioplasty balloons market share, detailed angioplasty balloons market segments, market trends and opportunities, and any further data you may need to thrive in the angioplasty balloons industry. This angioplasty balloons market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The angioplasty balloons market size has grown steadily in recent years. It will grow from $2.85 billion in 2025 to $2.98 billion in 2026 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to rising prevalence of coronary artery disease, increasing clinical adoption of percutaneous transluminal angioplasty, growth in hospital catheterization laboratory capacity, early availability of normal and compliant balloon catheters, expanding burden of peripheral artery disease.
The angioplasty balloons market size is expected to see steady growth in the next few years. It will grow to $3.47 billion in 2030 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to rising demand for drug-eluting and specialty balloons, increasing procedural volume in peripheral angioplasty, growth in complex lesion treatment requiring scoring and cutting balloons, expanding adoption of minimally invasive cardiovascular therapies, increasing investments in interventional cardiology infrastructure. Major trends in the forecast period include increasing adoption of drug-eluting balloons for complex coronary and peripheral lesions, rising utilization of non-compliant and semi-compliant balloons to enhance procedural precision, growing preference for scoring and cutting balloons in resistant and calcified stenoses, expansion of minimally invasive angioplasty interventions across cardiology and vascular care, increasing clinical shift toward balloon-based revascularization in patients unsuitable for stenting
.
The rising incidence of cardiovascular diseases is anticipated to drive the growth of the angioplasty balloons market in the coming years. Cardiovascular disease comprises a range of conditions affecting the heart and blood vessels, often resulting in serious complications such as heart attacks or strokes. The growing prevalence of cardiovascular disease is attributed to sedentary lifestyles, unhealthy dietary patterns, increasing obesity rates, and aging populations. Angioplasty balloons are used in the treatment of cardiovascular disease to dilate narrowed or obstructed blood vessels, restore adequate blood flow, and lower the risk of adverse events such as heart attacks or strokes. For example, in September 2024, according to data published by the Minnesota Department of Health, a US-based state health agency, nearly 30% of adults in Minnesota reported having high blood pressure in 2023, accounting for approximately 1.4 million individuals. In addition, in 2022, hypertensive diseases were identified as the underlying or contributing cause of death for 14,225 residents, representing nearly 28% of all deaths in the state. Consequently, the increasing burden of cardiovascular diseases is contributing to the expansion of the angioplasty balloons market.
Companies operating in the angioplasty balloons market are concentrating on the development of innovative solutions, such as advanced medical balloon forming systems, to improve precision in the manufacturing of high-pressure balloons used in critical cardiac procedures. An advanced medical balloon forming system is a technology designed to precisely manufacture compliant medical balloons for catheter-based applications. For instance, in June 2024, Interface Catheter Solutions, a US-based catheter technology company, introduced the BFM-5510 High Force Balloon Forming Machine. This advanced benchtop system is designed for producing low- and non-compliant polymer balloons used in angioplasty, stent deployment, and other essential cardiac interventions. Building on the BFM-3310 platform, the BFM-5510 HF utilizes beryllium copper molds to accurately shape extruded balloon tubing, ensuring strict quality control and tight tolerances across a broad range of balloon sizes and configurations. The system enhances production capabilities to support the manufacture of larger, thicker, and more complex medical balloons.
In September 2024, Quasar Medical, a US-based contract design and manufacturing organization, acquired Ridgeback Technologies for an undisclosed amount. This acquisition is intended to strengthen Quasar Medical's balloon catheter development and manufacturing capabilities by integrating Ridgeback Technologies' specialized design expertise, balloon fabrication technologies, and Galway-based production facility. The integration is expected to accelerate time-to-market for complex catheter and angioplasty balloon programs. Ridgeback Technologies is an Ireland-based company focused on the development and manufacturing of advanced balloon catheters, including folded, perfusion, and structural heart balloons.
Major companies operating in the angioplasty balloons market are Johnson & Johnson, Abbott Laboratories, Medtronic Plc, Boston Scientific Corporation, B. Braun SE, Terumo Corporation, Cook Medical, Biotronik SE, Merit Medical Systems Inc, Meril Life Sciences Pvt. Ltd., MicroPort Scientific Corporation, AngioDynamics, Cordis, iVascular, Hexacath, Balton Sp, Cardionovum, QualiMed Innovative Medizinprodukte GmbH, Translumina GmbH, Concept Medical Inc
North America was the largest region in the angioplasty balloons market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the angioplasty balloons market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the angioplasty balloons market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The angioplasty balloons market consists of sales of rapid exchange balloons, drug-eluting stent balloons, and microcatheter-compatible balloons. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Angioplasty Balloons Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses angioplasty balloons market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for angioplasty balloons ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The angioplasty balloons market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.